Tag: Caribou Biosciences
March 8, 2018
4 Gene Editing Technologies Explained
We look at four types of gene editing currently in clinical trials, as well as the pros and cons of...
October 5, 2017
4 Gene Therapy Stocks to Watch in 2017
At the halfway mark of 2017, here's a look at how these four gene therapy companies are performing so far...
February 15, 2017
The CRISPR-Cas9 Patent Dispute
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute. January 16, 2017
Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research
Horizon Discovery Group plc (LSE:HZD) (“Horizon” or the “Company”), the world leader in the application of gene editing technologies, today... December 16, 2016
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a... September 6, 2016
BIO Investor Forum 2016 Programming Announced
WASHINGTON–(BUSINESS WIRE)–The Biotechnology Innovation Organization (BIO) today announced programming for the 15th annual BIO Investor Forum. Held on October 18-19 at the...
March 10, 2016